alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-1021]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Pisgah Laboratories Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to 
                        **SUPPLEMENTARY INFORMATION**
                         listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 8, 2022. Such persons may also file a written request for a hearing on the application on or before August 8, 2022.
 ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to 
                        *https://www.regulations.gov*
                         and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on 
                        *https://www.regulations.gov.*
                         If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on March 9, 2022, Pisgah Laboratories Inc., 3222 Old Hendersonville Highway, Pisgah Forest, North Carolina 28768, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
Schedule4-Bromo-2,5-dimethoxyphenethylamine
7392
IMethylone (3,4-Methylenedioxy-N-methylcathinone)
7540
IDifenoxin
9168
IDiphenoxylate
9170
IILevorphanol
9220
IIMeperidine
9230
IIMethadone
9250
IIRemifentanil
9739
IITapentadol
9780
II
 The company plans to bulk manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration. Kristi O'Malley, Assistant Administrator.


[FR Doc. 2022-12197 Filed 6-6-22; 8:45 am] BILLING CODE P
```
 
 
VIX FUTURES - CBOE FUTURES EXCHANGE                                  Code-1170E1
OPTION AND FUTURES COMBINED POSITIONS AS OF 04/29/14          |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  Long  | Short  |Spreads |  Long  | Short  |  Long  | Short  |  Long  | Short
--------------------------------------------------------------------------------
($1000 X INDEX)                                      OPEN INTEREST:      365,215
COMMITMENTS
 110,843  156,329   82,661  149,727   98,821  343,231  337,811   21,984   27,404

CHANGES FROM 04/22/14 (CHANGE IN OPEN INTEREST:      3,085)
   4,245   15,674   -9,345    6,677   -3,235    1,577    3,094    1,508       -9

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADER
    30.4     42.8     22.6     41.0     27.1     94.0     92.5      6.0      7.5

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      192)
      61       75       78       41       36      146      156
```

----

Updated May 2, 2014
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

JOSE E. GUZMAN

, Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 18

- 37

[ March 15, 2018 ]

Appeal of order denying rule 3.800 motion from the Circuit Court for

the Fifteenth Judicial Circuit, Palm Beach County ; John S. Kastrenakes

, Judge; L.T. Case No. 502007CF000102A

.

Jose E. Guzman, Bushnell, pro se

.

No appearance required for appellee.

P ER C URIAM

.

Affirmed.

G ERBER

, C.J., D AMOORGIAN and C ONNER

, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
Independent Auditors' Report


The Board of Trustees of the
Travelers Series Trust:

In planning and performing our audits of the financial statements of
Convertible Bond, Strategic Stock, Disciplined Small Cap Stock, MFS Mid Cap
Growth, MFS Research, NWQ Large Cap, Jurika & Voyles Core Equity, Zero Coupon
Bond Fund Portfolio Series 2005, Travelers Quality Bond, Lazard International
Stock, MFS Emerging Growth, Federated High Yield, Federated Stock, Disciplined
Mid Cap Stock, U.S. Government Securities, Social Awareness Stock and
Utilities Portfolio (the "Funds") of Travelers Series Trust (the "Trust") for
the year ended December 31, 2000, we considered its internal control,
including control activities for safeguarding securities, in order to
determine our auditing procedures for the purpose of expressing our opinion on
the financial statements and to comply with the requirements of Form N-SAR,
not to provide assurance on the internal control.

The management of the Funds is responsible for establishing and maintaining
internal control.  In fulfilling this responsibility, estimates and judgments
by management are required to assess the expected benefits and related costs
of controls.  Generally, controls that are relevant to an audit pertain to the
entity's objective of preparing financial statements for external purposes
that are fairly presented in conformity with accounting principles generally
accepted in the United States of America. Those controls include the
safeguarding of assets against unauthorized acquisition, use, or disposition.

Because of inherent limitations in internal control, errors or fraud may occur
and not be detected.  Also, projection of any evaluation of internal control
to future periods is subject to the risk that it may become inadequate because
of changes in conditions or that the effectiveness of the design and operation
may deteriorate.

Our consideration of internal control would not necessarily disclose all
matters in internal control that might be material weaknesses under standards
established by the American Institute of Certified Public Accountants.  A
material weakness is a condition in which the design or operation of one or
more of the internal control components does not reduce to a relatively low
level the risk that misstatements caused by error or fraud in amounts that
would be material in relation to the financial statements being audited may
occur and not be detected within a timely period by employees in the normal
course of performing their assigned functions.  However, we noted no matters
involving internal control and its operation, including controls for
safeguarding securities, that we consider to be material weaknesses as defined
above as of December 31, 2000.

This report is intended solely for the information and use of management, the
Board of Trustees of the Trust, and the Securities and Exchange Commission and
is not intended to be and should not be used by anyone other than these
specified parties.


February 9, 2001
Exhibit
32.1





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002








In
connection with the Quarterly Report of Performance Health Technologies, Inc.
(the “Company”) on Form 10-Q for the period ending March 31, 2008 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I,
Robert D. Prunetti, President and Chief Executive Officer of the Company,
certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002:





1)           The
Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934; and





2)           The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.








Dated:
May 20, 2008






/s/ Robert D. Prunetti
              Robert
      D. Prunetti
              President
      and Chief Executive Officer
              (Principal
      Executive
Officer)
Cuitlahuac Tahua RIVERA, Petitioner v. CALIFORNIA

No. 19-5927

Supreme Court of the United States.

November 18, 2019

Petition for writ of certiorari to the Supreme Court of California denied.
MEMORANDUM OPINION

No. 04-11-00202-CV

IN RE Paul JONES

Original Proceeding1

PER CURIAM

Sitting: Catherine Stone, Chief Justice

Karen Angelini, Justice 

Marialyn Barnard, Justice

Delivered and Filed: March 23, 2011

PETITION FOR WRIT OF MANDAMUS DENIED

On March 18, 2011, relator filed a petition for writ of mandamus and a motion to stay the 

trial court proceedings. Relator complains the trial court erred (1) in finding the discovery 

propounded on real party in interest untimely and ordering that real party in interest was not 

required to respond, and (2) in excluding documents produced in response to subpoenas served 

on AT&T and Sprint Nextel Corp. However, mandamus will issue only to correct a clear abuse 

of discretion for which the relator has no adequate remedy at law. In re Prudential Ins. Co. of 

Am., 148 S.W.3d 124, 135 (Tex. 2004) (orig. proceeding); Walker v. Packer, 827 S.W.2d 833, 

839-40 (Tex. 1992) (orig. proceeding). Generally, a relator has no adequate remedy by appeal in 

 1 This proceeding arises out of Cause No. 336742, styled Paul Jones v. Pozzi Enterprises, Inc. d/b/a Border 

Construction Services, et al., pending in the County Court at Law No. 3, Bexar County, Texas, the Honorable David 

J. Rodriguez presiding. However, the order complained of was signed by the Honorable Irene Rios, presiding judge 

of County Court at Law No. 10, Bexar County, Texas. 
04-11-00202-CV

- 2 -

a discovery context when: (1) the appellate court would not be able to cure the trial court’s 

discovery error; (2) the party’s ability to present a viable claim or defense is vitiated or severely 

compromised by the erroneous discovery ruling to the extent that the party is effectively denied 

the ability to develop the merits of its case; or (3) the trial court’s discovery order disallows 

discovery which cannot be made a part of the appellate record, thereby denying the appellate 

court’s ability to evaluate the effect of the trial court’s error. See In re Colonial Pipeline Co., 

968 S.W.2d 938, 941 (Tex. 1998); In re K.L. & J. L.P., No. 04-10-00070-CV, 2010 WL 

5176846, at *2 (Tex. App.—San Antonio Dec. 10, 2010, orig. proceeding). While relator 

correctly lays out the adequate remedy by appeal standard, he fails to provide any analysis as to 

why he has no adequate remedy by appeal. Therefore, because relator has failed to establish he 

does not have an adequate remedy by appeal, the petition for writ of mandamus and the motion 

to stay are DENIED. See TEX. R. APP. P. 52.8(a).

PER CURIAM
Lawrence J. STRICKLAND, Petitioner v. UNITED STATES.

No. 18-9601

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER  REDDY ICE HOLDINGS, INC.  PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  (CHAPTER 98, TITLE 15 U.S.C. SS. 7241)

I,
Steven J. Janusek, certify that:

1.     I
have reviewed this quarterly report on Form 10-Q of Reddy Ice Holdings, Inc.;

2.     Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and
15(d)-15(f)) for the registrant and have:



5.     The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):



|                                                                 |  | 
|---------------------------------------------------------------- |  | 
|Date: April 30, 2009                                             |  | 
|/s/ STEVEN J. JANUSEK Steven J. Janusek,
Chief Financial Officer |  | 

---



QuickLinks
Glenn OLSON, Petitioner, v. Shannon MCCLOUD.

No. 19-6468

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Jose Bryan GONZALEZ, Petitioner v. UNITED STATES

No. 19-6178

Supreme Court of the United States.

November 12, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
---

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
  18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Scott M. Miller, Chief Financial Officer and Executive Vice President of Melt Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Quarterly Report on Form 10-QSB of Melt Inc. for the quarterly period ended June 30, 2007 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Melt Inc.

Dated: August 14, 2007

/s/ Scott M. MillerScott M. Miller
  Chief Financial Officer and Executive Vice President
  (Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by
Section 906, has been provided to Melt Inc. and will be retained by Melt Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

---
Presidential Documents

Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Presidential Documents 35075 

Presidential Determination No. 2022–17 of June 6, 2022 

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Electrolyzers, 

Fuel Cells, and Platinum Group Metals 

Memorandum for the Secretary of Energy 

Ensuring a robust, resilient, and sustainable domestic industrial base to 

meet the requirements of the clean energy economy is essential to our 

national security, a resilient energy sector, and the preservation of domestic 

critical infrastructure. Therefore, by the authority vested in me as President 

by the Constitution and the laws of the United States of America, including 

section 303 of the Defense Production Act of 1950, as amended (the ‘‘Act’’) 

(50 U.S.C. 4533), I hereby determine, pursuant to section 303(a)(5) of the 

Act, that: 

(1) electrolyzers, fuel cells, and platinum group metals are industrial resources, materials, or critical technology items essential to the national defense; 

(2) without Presidential action under section 303 of the Act, United States 

industry cannot reasonably be expected to provide the capability for the 

needed industrial resource, material, or critical technology item in a timely 

manner; and 

(3) purchases, purchase commitments, or other action pursuant to section 

303 of the Act are the most cost effective, expedient, and practical alternative 

method for meeting the need. 

Pursuant to section 303(a)(7)(B) of the Act, I find that action to expand 

the domestic production capability for electrolyzers, fuel cells, and platinum 

group metals is necessary to avert an industrial resource or critical technology 

item shortfall that would severely impair national defense capability. Therefore, I waive the requirements of section 303(a)(1)–(a)(6) of the Act for 

the purpose of expanding the domestic production capability for 

electrolyzers, fuel cells, and platinum group metals. 


lotter on DSK11XQN23PROD with FR_PREZDOC3
35076 Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Presidential Documents 

You are authorized and directed to publish this determination in the Federal 

Register. 

THE WHITE HOUSE, 

Washington, June 6, 2022 

[FR Doc. 2022–12585 

Filed 6–8–22; 8:45 am] 

Billing code 6450–01–P 


lotter on DSK11XQN23PROD with FR_PREZDOC3BIDEN.EPS</GPH>
Amy M. HICKS, petitioner, v. DALLAS COUNTY COMMUNITY COLLEGES.

No. 18-8553.

Supreme Court of the United States

Aug. 23, 2019.

Petition for rehearing denied.
Tracy Lane BEATTY, Petitioner, v. Lorie DAVIS, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 18-8429

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Marvin D. NOBLE, Petitioner, v. Shane JACKSON, Warden.

No. 19-8096.

Supreme Court of the United States.

May 26, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
Michael Bar aka MASON, Petitioner v. Daniel PARAMO, Warden

No. 19-147

Supreme Court of the United States.

October 15, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Robert GRAY, Petitioner v. UNITED STATES.

No. 19-5699

Supreme Court of the United States.

November 25, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Lakshmi ARUNACHALAM, Petitioner, v. UNITED STATES DISTRICT COURT FOR the NORTHERN DISTRICT OF CALIFORNIA, et al.

No. 18-9346

Supreme Court of the United States.

November 25, 2019

Petition for rehearing denied.
[ARTICLE] 6
[CIK] 0000880583
[NAME] UTILITIES PORTFOLIO
[SERIES]
   [NUMBER] 003
   [NAME] THE TRAVELERS SERIES TRUST
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   YEAR
[FISCAL-YEAR-END]                          DEC-31-1999
[PERIOD-END]                               DEC-31-1999
[INVESTMENTS-AT-COST]                       25,435,165
[INVESTMENTS-AT-VALUE]                      31,378,007
[RECEIVABLES]                                  366,906
[ASSETS-OTHER]                                       0
[OTHER-ITEMS-ASSETS]                                 0
[TOTAL-ASSETS]                              31,744,913
[PAYABLE-FOR-SECURITIES]                             0
[SENIOR-LONG-TERM-DEBT]                              0
[OTHER-ITEMS-LIABILITIES]                      331,833
[TOTAL-LIABILITIES]                            331,833
[SENIOR-EQUITY]                                      0
[PAID-IN-CAPITAL-COMMON]                    24,677,585
[SHARES-COMMON-STOCK]                        1,974,463
[SHARES-COMMON-PRIOR]                        1,915,301
[ACCUMULATED-NII-CURRENT]                      823,546
[OVERDISTRIBUTION-NII]                               0
[ACCUMULATED-NET-GAINS]                       (30,893)
[OVERDISTRIBUTION-GAINS]                             0
[ACCUM-APPREC-OR-DEPREC]                     5,942,842
[NET-ASSETS]                                31,413,080
[DIVIDEND-INCOME]                            1,015,481
[INTEREST-INCOME]                              108,892
[OTHER-INCOME]                                       0
[EXPENSES-NET]                                 300,648
[NET-INVESTMENT-INCOME]                        823,725
[REALIZED-GAINS-CURRENT]                      (30,893)
[APPREC-INCREASE-CURRENT]                    (754,466)
[NET-CHANGE-FROM-OPS]                           38,366
[EQUALIZATION]                                       0
[DISTRIBUTIONS-OF-INCOME]                      791,288
[DISTRIBUTIONS-OF-GAINS]                     1,799,094
[DISTRIBUTIONS-OTHER]                                0
[NUMBER-OF-SHARES-SOLD]                        414,864
[NUMBER-OF-SHARES-REDEEMED]                    510,525
[SHARES-REINVESTED]                            154,823
[NET-CHANGE-IN-ASSETS]                     (1,495,970)
[ACCUMULATED-NII-PRIOR]                        791,288
[ACCUMULATED-GAINS-PRIOR]                    1,799,097
[OVERDISTRIB-NII-PRIOR]                              0
[OVERDIST-NET-GAINS-PRIOR]                           0
[GROSS-ADVISORY-FEES]                          242,493
[INTEREST-EXPENSE]                                   0
[GROSS-EXPENSE]                                300,648
[AVERAGE-NET-ASSETS]                        34,150,003
[PER-SHARE-NAV-BEGIN]                            17.18
[PER-SHARE-NII]                                   0.41
[PER-SHARE-GAIN-APPREC]                         (0.36)
[PER-SHARE-DIVIDEND]                              0.40
[PER-SHARE-DISTRIBUTIONS]                         0.92
[RETURNS-OF-CAPITAL]                                 0
[PER-SHARE-NAV-END]                              15.91
[EXPENSE-RATIO]                                   0.88
</TABLE>
Dennis Andrew BALL, Petitioner v. CITY OF MARION, ILLINOIS.

No. 19-5828

Supreme Court of the United States.

November 4, 2019

Petition for writ of certiorari to the Appellate Court of Illinois, Fifth District denied.
Joel Marvin MUNT, Petitioner, v. Tom ROY, et al.

No. 18-9569

Supreme Court of the United States.

October 7, 2019

Motion of petitioner for leave to proceed *in forma pauperis* denied, and petition for a writ of certiorari to the Court of Appeals *330for the Eighth Circuit dismissed. See Rule 39.8. As petitioner has repeatedly abused this Court's process, the Clerk is directed not to accept any further petitions in noncriminal matters from petitioner unless the docketing fee required by Rule 38(a) is paid and petition submitted in compliance with Rule 33.1. See *Martin* v. *District of Columbia Court of Appeals* , 506 U.S. 1, 113 S.Ct. 397, 121 L.Ed.2d 305 (1992) (*per curiam* ).
Chavez MYERS, Petitioner v. UNITED STATES

No. 19-5932

Supreme Court of the United States.

October 21, 2019

Petition for writ of certiorari to the District of Columbia Court of Appeals denied.
Joseph D. BRADLEY, Petitioner, v. ALCO OIL & GAS COMPANY, LLC, et al.

No. 18-1384

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Seventh Circuit denied.
Gregory COOPER, Petitioner, v. Katy POOLE, et al.

No. 19-6637

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.